Theralase Technologies Inc. V.TLT

90 Day Period & 180 Day Period

[99942Apophis]

Newsletter dated November 29 had patients 25 to 30 being treated from the previous Newsletter dated August 30/2021 a time-frame of 3 months. A reasonable assumption would be 2 patients treated per month. 
We are now approaching the end of January/2022 which of course is 2 months since the last Newsletter or 4 of the 6 ( patients 25, 26, 27 & 28 ) that were announced treated should have hit that 90 point. 
The 90 day end point I believe is plus or minus 7 days! 

Looking at the 180 Day we had in the Newsletter of August 30/2021 patients 21 to 24 treated from the previous Newsletter dated June11/2021. That gives us 2 months 3 weeks, lets just say 1 patient for June and 1 for July  with 2 for August. That would now put patients 21 & 22 hitting their 180 point at the end of January/2022. 
 
End of February to first week of March in my opinion is Newsletter territory, however news of material substance could be released at any time.

[chry200030]

So then 22 patients treated for 1 year  in July. Is that right? If so, we should have some interesting developments in 2022. I read a news letter that puts the stock around .80. That would be a nice milestone to hit....

[tdon1229]

Can't see them being allowed to count any of the first 12 patients treated because of the gross under treatments they received.  The only ones they can count are those correctly treated twice as specified for the clinical trial.  All others are merely talking points and additional information, not properly treated Phase II trial subjects.  Same for the information about the long

[Yajne]

interesting perspective tdon1229, but I think FDA was completely aware of the first 12 treated when they granted fast track designation (FTD) in Nov 2020. I am hanging on statements made by Dr. Vera M. (below) in the last quarterly. Guess it depends on what you consider 'very soon' The data accrued to date for the TLD 1433-2 open label study for the treatment of NMIBC,

[CancerSlayer]

Agree Yajne....imo, before granting a BTD, the FDA simply wants to see "preliminary" clinical evidence that our ACT represents an improvement over other available therapies...currently, that bar has been set relatively low at ~40% (& that % imo is on the higher end of the BTD threshold due to the dire need for more patient-friendly options).  As for getting an FDA drug approval,

[tdon1229]

Actually, instead of 90 & 180 days, I meant to write (per the primary objective of the trial) 20-25 fully treated study patients demonstrating  Complete Response ("CR") ... at 360 days post primary treatment. I watched too much football this weekend, then worked from (faulty) memory.

[floatinketucky]

When the PI treated patients in the phase one study  they were cured of cancer 67% CR. On That rate they halted the study for the starting of the phase two study. The FDA will never be able un hear the bell that rang during that study. 67% CR with ONE TREATMENT! Say can we dial that back 30 pecent and still hit the bullseye??  PI says to himself... Hey lets dry run the first patients of